In comments to the White House Office of Science and Technology Policy, ITIF's Val Giddings argues there is no relationship between the degree of regulatory scrutiny a biotechnology product receives and the degree of hazard it represents. To enable and encourage innovation, the administration should restore that balance to the U.S. framework for biotechnology regulation.
